C

CSPC Pharmaceutical Group Ltd
HKEX:1093

Watchlist Manager
CSPC Pharmaceutical Group Ltd
HKEX:1093
Watchlist
Price: 4.8 HKD -0.21% Market Closed
Market Cap: 56.1B HKD
Have any thoughts about
CSPC Pharmaceutical Group Ltd?
Write Note

Net Margin
CSPC Pharmaceutical Group Ltd

17%
Current
19%
Average
4.5%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
17%
=
Net Income
5.2B
/
Revenue
30.3B

Net Margin Across Competitors

Country CN
Market Cap 57.1B HKD
Net Margin
17%
Country JP
Market Cap 776 550.9T JPY
Net Margin
-79%
Country US
Market Cap 741.7B USD
Net Margin
20%
Country UK
Market Cap 440.4B GBP
Net Margin
-4%
Country DK
Market Cap 2.8T DKK
Net Margin
35%
Country US
Market Cap 346.4B USD
Net Margin
17%
Country US
Market Cap 250B USD
Net Margin
19%
Country CH
Market Cap 199.8B CHF
Net Margin
20%
Country UK
Market Cap 161.8B GBP
Net Margin
13%
Country CH
Market Cap 171.7B CHF
Net Margin
35%
Country US
Market Cap 148.7B USD
Net Margin
7%
No Stocks Found

CSPC Pharmaceutical Group Ltd
Glance View

Market Cap
57.1B HKD
Industry
Pharmaceuticals

CSPC Pharmaceutical Group Ltd., a prominent player in the pharmaceutical industry, has charted a strategic path focused on innovation and a diversified portfolio. The company, with its roots in China, has emerged as a formidable force by blending traditional pharmaceutical manufacturing with a strong emphasis on research and development. CSPC's journey is characterized by a commitment to developing high-quality generic drugs, innovative therapeutics, and nutritional products. The company's core business revolves around the production and sale of a wide range of pharmaceuticals, including cardiovascular drugs, oncology treatments, and central nervous system therapies. By leveraging advanced technology and robust research initiatives, CSPC consistently delivers solutions that address both common and complex healthcare needs across the globe. With a strategic focus on both domestic and international markets, CSPC Pharmaceutical Group capitalizes on its extensive distribution network to maximize reach and impact. The company has made significant investments in its production capabilities to maintain stringent quality standards while achieving cost efficiency. Furthermore, CSPC's earnings are bolstered by its expanding pipeline of innovative drugs, developed in-house and through strategic collaborations, which aims to capture emerging therapeutic areas. Overall, CSPC's blend of traditional pharmaceutical expertise, a focus on innovation, and strategic market positioning enables it to maintain a strong operational foothold and to consistently drive revenue growth in an ever-evolving industry landscape.

Intrinsic Value
7.28 HKD
Undervaluation 34%
Intrinsic Value
Price
C

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
17%
=
Net Income
5.2B
/
Revenue
30.3B
What is the Net Margin of CSPC Pharmaceutical Group Ltd?

Based on CSPC Pharmaceutical Group Ltd's most recent financial statements, the company has Net Margin of 17%.